TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Double-blind Cross-over Trial Evaluating the Role of Frequencies on Spinal Cord Stimulation in the Management of Failed Back Surgery Syndrome (SCS Frequency Study)
Brief Summary: The purpose of this study is to evaluate the role of frequency settings on spinal cord stimulation in the management of Failed Back Surgery Syndrome (SCS Frequency Study).


Options:
A: Arm Label: Burst spinal cord stimulation (SCS); Type: EXPERIMENTAL; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Arm Label: sham spinal cord stimulation (SCS); Type: SHAM_COMPARATOR; Interventions: Procedure: Burst Spinal Cord Stimulation, Procedure: Sham spinal cord stimulation | Intervention Type: PROCEDURE; Name: Burst Spinal Cord Stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS) | Intervention Type: PROCEDURE; Name: Sham spinal cord stimulation; Assigned to Arm(s): Burst spinal cord stimulation (SCS), sham spinal cord stimulation (SCS)
B: Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Arm Label: 1200 Hz; Type: EXPERIMENTAL; Interventions: Device: 1200 Hz | Arm Label: 3030 Hz; Type: EXPERIMENTAL; Interventions: Device: 3030 Hz | Arm Label: 5882 Hz; Type: EXPERIMENTAL; Interventions: Device: 5882 Hz | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham | Intervention Type: DEVICE; Name: 1200 Hz; Assigned to Arm(s): 1200 Hz | Intervention Type: DEVICE; Name: 3030 Hz; Assigned to Arm(s): 3030 Hz | Intervention Type: DEVICE; Name: 5882 Hz; Assigned to Arm(s): 5882 Hz
C: Arm Label: Tonic; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Arm Label: Sham; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Arm Label: burst; Type: EXPERIMENTAL; Interventions: Procedure: dorsal column stimulator | Intervention Type: PROCEDURE; Name: dorsal column stimulator; Assigned to Arm(s): Sham, Tonic, burst
D: Arm Label: GMI and Desensitization; Type: EXPERIMENTAL; Interventions: Behavioral: GMI and Desensitization | Arm Label: Desensitization; Type: EXPERIMENTAL; Interventions: Behavioral: Desensitization | Intervention Type: BEHAVIORAL; Name: GMI and Desensitization; Assigned to Arm(s): GMI and Desensitization | Intervention Type: BEHAVIORAL; Name: Desensitization; Assigned to Arm(s): Desensitization

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Double-blind Cross-over Trial Evaluating the Role of Frequencies on Spinal Cord Stimulation in the Management of Failed Back Surgery Syndrome (SCS Frequency Study)
Brief Summary: The purpose of this study is to evaluate the role of frequency settings on spinal cord stimulation in the management of Failed Back Surgery Syndrome (SCS Frequency Study).


Options:
A: Arm Label: CMM; Type: OTHER; Interventions: Other: CMM | Arm Label: HF10 + CMM; Type: ACTIVE_COMPARATOR; Interventions: Device: HF10 Therapy, Other: CMM | Intervention Type: DEVICE; Name: HF10 Therapy; Assigned to Arm(s): HF10 + CMM | Intervention Type: OTHER; Name: CMM; Assigned to Arm(s): CMM, HF10 + CMM
B: Arm Label: Spinal Cord Stimulation (SCS); Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal Cord Stimulation (SCS), Other: Physiotherapy | Arm Label: Physiotherapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Spinal Cord Stimulation (SCS), Other: Physiotherapy | Intervention Type: DEVICE; Name: Spinal Cord Stimulation (SCS); Assigned to Arm(s): Physiotherapy, Spinal Cord Stimulation (SCS) | Intervention Type: OTHER; Name: Physiotherapy; Assigned to Arm(s): Physiotherapy, Spinal Cord Stimulation (SCS)
C: Arm Label: Group A - active treatment; Type: EXPERIMENTAL; Interventions: Device: Spinal cord stimulation by implanted device. | Arm Label: Group B - conservative management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal cord stimulation by implanted device.; Assigned to Arm(s): Group A - active treatment
D: Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Arm Label: 1200 Hz; Type: EXPERIMENTAL; Interventions: Device: 1200 Hz | Arm Label: 3030 Hz; Type: EXPERIMENTAL; Interventions: Device: 3030 Hz | Arm Label: 5882 Hz; Type: EXPERIMENTAL; Interventions: Device: 5882 Hz | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham | Intervention Type: DEVICE; Name: 1200 Hz; Assigned to Arm(s): 1200 Hz | Intervention Type: DEVICE; Name: 3030 Hz; Assigned to Arm(s): 3030 Hz | Intervention Type: DEVICE; Name: 5882 Hz; Assigned to Arm(s): 5882 Hz

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Controlled Double-blind Cross-over Trial Evaluating the Role of Frequencies on Spinal Cord Stimulation in the Management of Failed Back Surgery Syndrome (SCS Frequency Study)
Brief Summary: The purpose of this study is to evaluate the role of frequency settings on spinal cord stimulation in the management of Failed Back Surgery Syndrome (SCS Frequency Study).


Options:
A: Arm Label: Active Lead (AL); Type: ACTIVE_COMPARATOR; Interventions: Device: Nevro Senza System (HF10 Therapy) | Arm Label: Sham Lead (SL); Type: SHAM_COMPARATOR; Interventions: Device: Nevro Senza System (HF10 Therapy) | Intervention Type: DEVICE; Name: Nevro Senza System (HF10 Therapy); Assigned to Arm(s): Active Lead (AL), Sham Lead (SL)
B: Arm Label: Group A - active treatment; Type: EXPERIMENTAL; Interventions: Device: Spinal cord stimulation by implanted device. | Arm Label: Group B - conservative management; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Spinal cord stimulation by implanted device.; Assigned to Arm(s): Group A - active treatment
C: Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Device: Sham | Arm Label: 1200 Hz; Type: EXPERIMENTAL; Interventions: Device: 1200 Hz | Arm Label: 3030 Hz; Type: EXPERIMENTAL; Interventions: Device: 3030 Hz | Arm Label: 5882 Hz; Type: EXPERIMENTAL; Interventions: Device: 5882 Hz | Intervention Type: DEVICE; Name: Sham; Assigned to Arm(s): Sham | Intervention Type: DEVICE; Name: 1200 Hz; Assigned to Arm(s): 1200 Hz | Intervention Type: DEVICE; Name: 3030 Hz; Assigned to Arm(s): 3030 Hz | Intervention Type: DEVICE; Name: 5882 Hz; Assigned to Arm(s): 5882 Hz
D: Arm Label: Spinal Cord Stimulation; Type: EXPERIMENTAL; Interventions: Device: WaveWriter | Arm Label: Conventional Medical Management; Type: OTHER; Interventions: Other: Conventional Medical Managament | Intervention Type: DEVICE; Name: WaveWriter; Assigned to Arm(s): Spinal Cord Stimulation | Intervention Type: OTHER; Name: Conventional Medical Managament; Assigned to Arm(s): Conventional Medical Management

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Pharmaceutical Care in Patients With Bipolar I Disorder at St John of God Clinic. Randomized Trial.
Brief Summary: This project aims, through pharmaceutical care in patients with Bipolar I Disorder, improve compliance and adherence rate, associated with greater effectiveness and safety of drug therapy to help achieve therapeutic goals, and finally to improving the quality of life of patients.


Options:
A: Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Other: Education | Arm Label: Pharmaceutical Care; Type: ACTIVE_COMPARATOR; Interventions: Other: Pharmaceutical Care | Intervention Type: OTHER; Name: Pharmaceutical Care; Assigned to Arm(s): Pharmaceutical Care | Intervention Type: OTHER; Name: Education; Assigned to Arm(s): Control
B: Arm Label: Extended Treatment Group; Type: EXPERIMENTAL; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference, Behavioral: Comprehensive Medication Management | Arm Label: Usual Treatment Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Glucose and lipids, Device: Glycosylated Hemoglobin A1c, Device: Blood Pressure and Heart Rate, Device: Body mass index, Device: Waist and Hip circumference | Intervention Type: DEVICE; Name: Glucose and lipids; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Glycosylated Hemoglobin A1c; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Blood Pressure and Heart Rate; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Body mass index; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: DEVICE; Name: Waist and Hip circumference; Assigned to Arm(s): Extended Treatment Group, Usual Treatment Group | Intervention Type: BEHAVIORAL; Name: Comprehensive Medication Management; Assigned to Arm(s): Extended Treatment Group
C: Arm Label: 1; Type: N/A; Interventions: Other: 1 | Arm Label: 2; Type: N/A; Interventions: Other: 2 | Intervention Type: OTHER; Name: 1; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: 2; Assigned to Arm(s): 2
D: Arm Label: Patient-centred tailored intervention; Type: EXPERIMENTAL; Interventions: Other: Medicines Advice Service | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Medicines Advice Service; Assigned to Arm(s): Patient-centred tailored intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Endoscopic Resection of High Grade(TA, T1, Cis)Non-muscle Invasive Bladder Tumors: Modification of Usual Management of This Resection by Using the Blue Light and Evaluation of the Outcome: Should we Maintain the Dogma of Second Endoscopic Resection as a Principle?
Brief Summary: To confirm the benefit of endoscopic resection under fluorescence and blue light of high grade non-muscle invasive bladder tumor, and verifying if the second endoscopic resection recommended nowadays can be deleted.


Options:
A: Arm Label: Mitomycin C; Type: EXPERIMENTAL; Interventions: Drug: Mitomycin C | Arm Label: Gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: No intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Mitomycin C; Assigned to Arm(s): Mitomycin C | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine
B: Arm Label: Standard White Light Cystoscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Standard white light cystoscopy | Arm Label: Standard White Light and Hexvix Fluorescence Cystoscopy; Type: EXPERIMENTAL; Interventions: Drug: Hexvix, Procedure: Standard white light cystoscopy | Intervention Type: DRUG; Name: Hexvix; Assigned to Arm(s): Standard White Light and Hexvix Fluorescence Cystoscopy | Intervention Type: PROCEDURE; Name: Standard white light cystoscopy; Assigned to Arm(s): Standard White Light Cystoscopy, Standard White Light and Hexvix Fluorescence Cystoscopy
C: Arm Label: Cohort 1: Erdafitinib; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 1: Investigators Choice; Type: ACTIVE_COMPARATOR; Interventions: Drug: Investigator Choice (Gemcitabine), Drug: Investigator Choice (Mitomycin C) | Arm Label: Cohort 2; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Arm Label: Cohort 3; Type: EXPERIMENTAL; Interventions: Drug: Erdafitinib | Intervention Type: DRUG; Name: Erdafitinib; Assigned to Arm(s): Cohort 1: Erdafitinib, Cohort 2, Cohort 3 | Intervention Type: DRUG; Name: Investigator Choice (Gemcitabine); Assigned to Arm(s): Cohort 1: Investigators Choice | Intervention Type: DRUG; Name: Investigator Choice (Mitomycin C); Assigned to Arm(s): Cohort 1: Investigators Choice
D: Arm Label: Resection under blue light; Type: EXPERIMENTAL; Interventions: Other: Endoscopic resection under blue light (Hexvix®) | Arm Label: Resection under white light; Type: ACTIVE_COMPARATOR; Interventions: Other: Endoscopic resection under blue light (Hexvix®) | Intervention Type: OTHER; Name: Endoscopic resection under blue light (Hexvix®); Assigned to Arm(s): Resection under blue light, Resection under white light

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Strongest Families Finland Canada: Family-based Prevention and Treatment Program of Early Childhood Disruptive Behavior
Brief Summary: The goal of the Strongest Families Finland Canada project is to help parents develop skills to strengthen their families and reduce disruptive behavior in their 4 year old children.


Options:
A: Arm Label: Usual Care control (Parenting tips); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Strongest Families; Type: EXPERIMENTAL; Interventions: Behavioral: Strongest Families | Intervention Type: BEHAVIORAL; Name: Strongest Families; Assigned to Arm(s): Strongest Families
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Home visitation through pregnancy; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Arm Label: Home visitation through age 2; Type: EXPERIMENTAL; Interventions: Behavioral: nurse home visitation | Intervention Type: BEHAVIORAL; Name: nurse home visitation; Assigned to Arm(s): Home visitation through age 2, Home visitation through pregnancy
C: Arm Label: Behavioral Parent Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Behavioral Parent Training | Arm Label: Behavioral Parent Training - Enhanced; Type: EXPERIMENTAL; Interventions: Behavioral: Behavioral Parent Training | Intervention Type: BEHAVIORAL; Name: Behavioral Parent Training; Assigned to Arm(s): Behavioral Parent Training, Behavioral Parent Training - Enhanced
D: Arm Label: Helping the Noncompliant Child (HNC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Helping the Noncompliant Child (HNC) | Arm Label: Technology-Enhanced HNC (TE-HNC); Type: EXPERIMENTAL; Interventions: Behavioral: Technology-Enhanced Helping the Noncompliant Child (TE-HNC) | Intervention Type: BEHAVIORAL; Name: Helping the Noncompliant Child (HNC); Assigned to Arm(s): Helping the Noncompliant Child (HNC) | Intervention Type: BEHAVIORAL; Name: Technology-Enhanced Helping the Noncompliant Child (TE-HNC); Assigned to Arm(s): Technology-Enhanced HNC (TE-HNC)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Open-label Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults Aged 50 Years or Older
Brief Summary: The purpose of this study is to assess the safety and immunogenicity of the GSK Biologicals' HZ vaccine 1437173A administered on either a 0,2-; 0,6- or 0,12-month schedule in adults aged 50 years or above, as the immunogenicity of the HZ vaccine administered at intervals longer than two months is not known.


Options:
A: Arm Label: HZ/su-0,2 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: HZ/su-0,6 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Arm Label: HZ/su-0,12 Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes zoster vaccine GSK1437173A | Intervention Type: BIOLOGICAL; Name: Herpes zoster vaccine GSK1437173A; Assigned to Arm(s): HZ/su-0,12 Group, HZ/su-0,2 Group, HZ/su-0,6 Group
B: Arm Label: Concomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Arm Label: Nonconcomitant Vaccination; Type: EXPERIMENTAL; Interventions: Biological: ZOSTAVAX™, Biological: Placebo to ZOSTAVAX™, Biological: Influenza Vaccine | Intervention Type: BIOLOGICAL; Name: ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Placebo to ZOSTAVAX™; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination | Intervention Type: BIOLOGICAL; Name: Influenza Vaccine; Assigned to Arm(s): Concomitant Vaccination, Nonconcomitant Vaccination
C: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Assigned to Arm(s): Control Group, GSK1437173A Group
D: Arm Label: NBP608; Type: EXPERIMENTAL; Interventions: Biological: NBP608 | Arm Label: Zostavax; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: NBP608; Assigned to Arm(s): NBP608 | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Zostavax

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Integrating Substance Abuse Assessment & Intervention in Primary Care Settings
Brief Summary: The purposes of this study are to: 1) implement a high fidelity Screening, Brief Intervention and Referral to Treatment (SBIRT) protocol with computerized screening technology into three primary care clinics in urban Philadelphia; 2) conduct a randomized controlled trial to determine if an expanded SBIRT (SBIRT+) will help patients attend more specialty substance abuse treatment sessions and reduce substance use compared to SBIRT; 3) conduct a process evaluation of SBIRT+ at the three collaborating clinics consisting of focus groups and structured interviews to assess implementation barriers and workforce attitudinal shifts; and 4) provide an excellent clinical research training environment for undergraduate and graduate students from Lincoln University.


Options:
A: Arm Label: NCMIT; Type: EXPERIMENTAL; Interventions: Behavioral: NCMIT | Arm Label: SCMIT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SCMIT | Intervention Type: BEHAVIORAL; Name: NCMIT; Assigned to Arm(s): NCMIT | Intervention Type: BEHAVIORAL; Name: SCMIT; Assigned to Arm(s): SCMIT
B: Intervention Type: BEHAVIORAL; Name: Peer Mentoring Intervention for HCV-Infected IDUs; Assigned to Arm(s): N/A
C: Arm Label: Control Group: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Network Interview Recipients; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Network Interview | Intervention Type: BEHAVIORAL; Name: Motivational Network Interview; Assigned to Arm(s): Motivational Network Interview Recipients
D: Arm Label: SBIRT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SBIRT | Arm Label: SBIRT+; Type: EXPERIMENTAL; Interventions: Behavioral: SBIRT+ | Intervention Type: BEHAVIORAL; Name: SBIRT; Assigned to Arm(s): SBIRT | Intervention Type: BEHAVIORAL; Name: SBIRT+; Assigned to Arm(s): SBIRT+

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Enhanced Motor Recovery Using Serotonergic Agents in Stroke
Brief Summary: The information derived from this study will be critical to establishing appropriate rehabilitative interventions post-stroke. In particular, traditional use of pharmacological agents to alter motor function post-stroke is directed primarily at reducing the "positive" signs following upper motor neuron lesion, in particular spasticity, or enhanced, velocity-dependent stretch reflex responses to imposed stretch. While pharmacological management of spasticity certainly suppresses clinical and quantitative measures of hypertonia, there is little improvement in functional performance. In contrast, preliminary data on the administration of 5HT agents following neurological injury indicates an increase in motor performance (Pariente 2001) and recovery (Dam 1996), despite an increase in spastic motor activity (Stolp-Smith 1999; see Preliminary Data below). Understanding methods to maximize function following stroke despite potential, short-term increases in spastic motor activity may improve therapeutic intervention strategies. The general objective of this study is therefore to:

1. quantify the effects of short-term SSRI administration on voluntary and spastic motor behaviors in individuals with chronic spastic hemiparesis,
2. identify the changes in impairments and functional recovery of walking ability during BWSTT with the presence or absence of SSRIs.


Options:
A: Arm Label: SSRI; Type: EXPERIMENTAL; Interventions: Drug: SSRI | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: SSRI; Assigned to Arm(s): SSRI | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: sugar pill | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): escitalopram | Intervention Type: DRUG; Name: sugar pill; Assigned to Arm(s): placebo
C: Arm Label: Selective Serotonin Reuptake Inhibitors; Type: ACTIVE_COMPARATOR; Interventions: Drug: Citalopram | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Selective Serotonin Reuptake Inhibitors | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1 Problem Solving Therapy; Type: EXPERIMENTAL; Interventions: Behavioral: Problem Solving Therapy | Arm Label: 2. Escitalopram; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Arm Label: 3 Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BEHAVIORAL; Name: Problem Solving Therapy; Assigned to Arm(s): 1 Problem Solving Therapy | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): 2. Escitalopram | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): 3 Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Improved Accessibility of EmONC Services for Maternal and Newborn Health: a Community Based Project.
Brief Summary: The purpose of this study is to determine whether an integrated EmONC package (community mobilization, training of community-based health care providers and a maternal and neonatal health pack) reduce perinatal and neonatal mortality.


Options:
A: Arm Label: EmONC package; Type: EXPERIMENTAL; Interventions: Behavioral: EmONC package | Arm Label: Standard of care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: EmONC package; Assigned to Arm(s): EmONC package
B: Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHW-Visit; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Arm Label: CHW-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: Delivery of a Post-Partum Package | Intervention Type: BEHAVIORAL; Name: Delivery of a Post-Partum Package; Assigned to Arm(s): CHW-Phone, CHW-Visit
C: Arm Label: Control Condition; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: CHARM Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: CHARM | Intervention Type: BEHAVIORAL; Name: CHARM; Assigned to Arm(s): CHARM Intervention
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Community Health Workers; Type: EXPERIMENTAL; Interventions: Behavioral: community health workers | Intervention Type: BEHAVIORAL; Name: community health workers; Assigned to Arm(s): Community Health Workers

Answer: A